Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First in Human, Open-label, Dose Escalation and Dose Expansion Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors

NCT04958434 is registered in ClinicalTrials.gov with Suzhou Transcenta Therapeutics Co., Ltd. as lead sponsor.

NCT NCT04958434
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04958434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First in Human, Open-label, Dose Escalation and Dose Expansion Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Suzhou Transcenta Therapeutics Co., Ltd.
Phase
Phase 1
Overall status
Terminated
Start date
June 11, 2021
Completion date
September 30, 2023
Enrollment
19 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic cancers, metastatic human papillomavirus-related malignant neoplasm